Available online on 15.12.2024 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access Full Text Article  Review Article

Pharmaceutical Resilience

Kiran Bhosale ¹*, Omkar Baradkar ², Sandip Lakade ²

¹ Assistant Professor, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, India

² Student, Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune, India

 

 

Pharmaceutical resilience refers to the ability of the pharmaceutical industry to withstand, adapt to, and recover from disruptions across all its fields, ensuring the continuous availability of essential medications. In manufacturing, resilience is about maintaining production and scaling up operations during crises, while supply chain management focuses on creating robust, adaptable networks that can handle risks such as supply shortages and geopolitical tensions. Regulatory affairs play a crucial role in ensuring that approval processes are flexible and can expedite the distribution of critical drugs during emergencies. In research and development (R&D), resilience is tied to the rapid innovation and development of new treatments, leveraging advanced technologies and collaborative efforts. ^17,15

Healthcare system integration ensures that medications reach patients effectively, even during disruptions, supported by telemedicine and patient-centred approaches. Global and local collaboration, including public-private partnerships and international cooperation, is essential for coordinated responses to health challenges. Risk management and preparedness involve planning and scenario testing to mitigate the impact of potential disruptions. Ensuring equity and access is critical, particularly for vulnerable populations, while sustainability focuses on minimizing environmental impact and securing long-term resource availability. Crisis response and recovery strategies enable rapid mobilization and restoration of operations, guided by ethical considerations that balance public health needs with fairness and transparency. ^28,18

Technological innovation, such as digital transformation and advanced manufacturing, is key to enhancing resilience, with economic resilience ensuring that the industry can withstand financial disruptions. Lastly, future directions in pharmaceutical resilience emphasize ongoing innovation and the development of new strategies to ensure the industry remains adaptable and robust in the face of emerging global challenges.

2.1. Supply Chain Management

• Diversification of Sources: Reducing reliance on a single country or supplier for raw materials and active pharmaceutical ingredients (APIs). Inventory Management: Developing strategies for stockpiling essential drugs and maintaining optimal inventory levels.^6,17
• Logistics and Distribution Networks: Enhancing the efficiency and reliability of transportation and delivery systems to ensure timely availability of medicines.^1,30,55

2.2. Regulatory Framework

• Adaptive Regulations: Establishing flexible regulatory processes that can be expedited during emergencies to facilitate the rapid approval and distribution of critical drugs.
• Global Harmonization: Promoting the alignment of regulatory standards across countries to streamline drug approval and distribution internationally.
• Quality Assurance: Maintaining strict quality control measures to ensure the safety and efficacy of pharmaceutical products, even during crises.²

2.3. Research and Development (R&D)

• Innovation in Drug Development: Encouraging the continuous development of new drugs and therapies, especially for emerging and re-emerging diseases.
• Rapid Response Capabilities: Investing in technologies and platforms that enable quick development and testing of vaccines and treatments in response to health emergencies.
• Collaboration in R&D: Fostering partnerships between public and private sectors, as well as international collaborations, to accelerate innovation.^18,36

2.4. Manufacturing Capabilities

• Scalability: Developing manufacturing processes that can be quickly scaled up to meet increased demand during emergencies.³⁸
• Sustainable Practices: Implementing environmentally sustainable practices in pharmaceutical manufacturing.
• Resilient Infrastructure: Ensuring that manufacturing facilities are resilient to disruptions, such as natural disasters or supply chain interruptions. ³⁰

2.5. Healthcare System Integration

• Coordination with Healthcare Providers: Ensuring that healthcare providers have access to essential medicines and the ability to manage supply effectively.^4,52
• Telemedicine and Digital Health: Leveraging technology to maintain patient care and medication delivery, especially during disruptions to traditional healthcare services.⁷
• Patient Education and Communication: Providing clear and accurate information to patients about drug availability and usage during crises.⁵⁴

2.6. Global and Local Collaboration

• International Cooperation: Strengthening global partnerships to coordinate responses to pandemics and other health crises.
• Public-Private Partnerships: Encouraging collaboration between governments, NGOs, and pharmaceutical companies to build a more resilient pharmaceutical ecosystem.⁵³
• Community Engagement: Involving local communities in planning and response efforts to ensure that interventions are effective and culturally appropriate.⁵¹

2.7. Risk Management and Preparedness

• Scenario Planning: Conducting simulations and risk assessments to prepare for various types of disruptions. ^2,23
• Emergency Preparedness Plans: Developing and regularly updating plans for responding to supply chain disruptions, pandemics, and other crises.³⁶
• Continuous Monitoring and Improvement: Implementing systems for ongoing monitoring of risks and vulnerabilities, with mechanisms for continuous improvement.⁴⁵
  2. Equity and Access:

Equitable Distribution: Ensuring that all populations, particularly those in low-income or remote areas, have access to essential medications.¹²

• Affordability: Implementing pricing strategies and policies that make medicines affordable for all, especially during crises.
• Targeted Interventions: Developing specific strategies to address the needs of vulnerable populations, including the elderly, people with chronic conditions, and marginalized communities.¹³

2.9. Sustainability and Environmental Impact

• Eco-Friendly Manufacturing: Reducing the environmental footprint of pharmaceutical manufacturing processes.⁴⁴
• Waste Management: Implementing efficient waste management practices to minimize the environmental impact of pharmaceutical waste.
• Sustainable Sourcing: Ensuring that raw materials are sourced in a way that is sustainable and does not deplete natural resources.

2.10. Innovation in Technology and Infrastructure

• Advanced Manufacturing Technologies: Investing in technologies such as 3D printing and biotechnology to enhance manufacturing resilience.⁵
• Digital Supply Chain Management: Utilizing digital tools and platforms to enhance the transparency and efficiency of supply chain management.⁹
• Blockchain for Traceability: Implementing blockchain technology to ensure the traceability and authenticity of pharmaceutical products.

2.11. Crisis Response and Recovery

• Rapid Mobilization: Developing the capacity for quick mobilization of resources, including personnel, funds, and supplies, during emergencies.¹⁴
• Resilient Recovery Plans: Establishing plans for the rapid recovery of pharmaceutical production and distribution following a disruption.³³
• Learning from Crises: Creating systems for capturing and analysing lessons learned from past crises to improve future resilience efforts.⁴⁴

2.12. Legal and Ethical Considerations

• Intellectual Property Flexibility: Balancing intellectual property rights with the need for widespread access to essential medicines during crises.
• Ethical Drug Distribution: Ensuring that drug distribution during emergencies is conducted ethically, with a focus on equity and fairness.
• Liability and Risk Sharing: Addressing legal issues related to liability and risk sharing among stakeholders in the pharmaceutical industry.⁵¹

These contents collectively form the foundation of pharmaceutical resilience, ensuring that the industry and healthcare systems are better equipped to handle disruptions, protect public health, and sustain essential services under all circumstances.Top of FormBottom of Form

Pharmaceutical resilience refers to the capacity of the pharmaceutical industry, health systems, and associated supply chains to withstand, adapt to, and rapidly recover from disruptions while maintaining the ability to provide critical medications and healthcare services. This concept has gained increasing attention, especially in the wake of global crises such as the COVID-19 pandemic, which highlighted vulnerabilities in drug manufacturing, distribution, and access. 

3. Key Components of Pharmaceutical Resilience:

3.1. Supply Chain Robustness: 

Ensuring that supply chains for raw materials, active pharmaceutical ingredients (APIs), and finished products are diversified and not overly reliant on a single source or region.³¹

3.2. Regulatory Flexibility: Developing adaptable regulatory frameworks that can expedite the approval and distribution of essential medications during emergencies without compromising safety and efficacy.⁴⁵

3.3.Innovation and R&D: Encouraging continuous innovation in drug development, including rapid research and development of new therapies and vaccines in response to emerging health threats.³⁶

3.4.Stockpiling and Distribution: Maintaining strategic reserves of critical medications and establishing efficient distribution networks to prevent shortages during crises.

3.5Collaborative Networks: Fostering collaboration among governments, international organizations, pharmaceutical    companies, and other stakeholders to ensure a coordinated response to global health challenges

3.5.1. Sustainability: Implementing sustainable practices in pharmaceutical manufacturing and distribution to minimize environmental impact and ensure long-term viability.

3.5.2. Patient Access: Ensuring that all populations, particularly vulnerable and marginalized groups, have equitable access to essential medications during both normal times and emergencies.

4. Why we are studying the term of pharmaceutical resilience: 

4.1. Addressing Global Health Challenges⁴

4.2. Ensuring Continuity of Care²³

4.3. Promoting Public Health Security

4.4. Supporting Innovation and Rapid Response

4.5. Enhancing Global Collaboration

4.6. Building Sustainable Systems

4.7. Ensuring Equitable Access

4.8. Preparing for Future Crises

4.9. Strengthening Healthcare Systems

4.10. Economic Stability

4.11. Policy Development

In summary, studying pharmaceutical resilience is critical for preparing healthcare systems and the pharmaceutical industry to handle disruptions, protect public health, and ensure that essential medications remain available to those who need them, regardless of the circumstances. It is about building a more robust, adaptable, and equitable healthcare infrastructure that can respond effectively to both current and future challenges.

 

 

 

 

 

Top of Form

 Figure 1: pie chart representing the key components of pharmaceutical resilience⁵

Bottom of Form

 

 

Pharmaceutical resilience is critically important in India due to the country's significant role in the global pharmaceutical industry and its large population that relies on affordable and accessible medicines. Here’s why pharmaceutical resilience is particularly important in India:²⁸

 

Table 1: significant role in the global pharmaceutical industry⁵

 
 

5. Strategies to increase the pharmaceutical supply chain resilience to sanction ³¹

Here’s a detailed overview of strategies to increase resilience in the pharmaceutical supply chain:

5.1. Diversification of Suppliers

•   Description: Engage multiple suppliers across various geographic regions to avoid reliance on a single source.
• - Implementation: Identify critical components and raw materials, then map out alternative suppliers. Establish relationships with both local and international vendors to ensure a wider safety net.⁶

5.2. Local Sourcing

• Description: Prioritize sourcing raw materials and components from local or regional suppliers to minimize exposure to international sanctions and reduce shipping times.
•  Implementation: Conduct a feasibility study to identify local suppliers that can meet quality standards. Build partnerships with local businesses to encourage resilience.

5.3. Robust Risk Assessment

•  Description: Regularly evaluate potential risks in the supply chain, including geopolitical factors, natural disasters, and economic changes.
•  Implementation: Create a risk assessment framework that includes scoring systems for various risk factors. Schedule regular reviews and updates to the risk management plan based on current events.⁹

5.4. Inventory Management

•  Description: Maintain higher inventory levels of critical products and materials, implementing safety stock policies to cushion against shortages.
•  Implementation: Analyze historical data to determine optimal inventory levels. Use just-in-case (JIC) inventory strategies for essential products while balancing costs.²³

 5.5. Alternative Transportation Routes

•  Description: Develop and identify alternative logistics routes and methods to ensure the timely delivery of products, especially if traditional routes are compromised.
•  Implementation: Map out potential alternative shipping routes and methods, including air, sea, and land options. Collaborate with logistics partners to establish contingency plans.⁴⁵

 

5.6. Collaboration and Partnerships

•  Description: Form strategic alliances with other pharmaceutical companies, healthcare providers, and governmental agencies to share resources, knowledge, and capabilities.
• Implementation: Participate in industry groups and forums to foster relationships. Consider joint ventures or partnerships to share risks and resources.

5.7. Technology and Data Analytics

•  Description: Leverage advanced technologies like AI, blockchain, and IoT for real-time tracking, data analysis, and enhanced decision-making.
•  Implementation: Invest in data management systems that allow for end-to-end visibility of the supply chain. Use predictive analytics to forecast demand and identify potential disruptions.

5.8. Regulatory Knowledge and Adaptability

•  Description: Stay informed about current regulations and potential sanctions to ensure compliance and adaptability in operations.
•  Implementation: Regularly train staff on regulatory changes and maintain an updated database of relevant regulations. Engage legal experts to navigate complex compliance landscapes.

5.9. Scenario Planning and Simulation

•  Description: Conduct simulations to prepare for various scenarios, helping teams understand potential impacts and develop response plans.
•  Implementation: Design tabletop exercises to role-play responses to different disruption scenarios. Analyze the outcomes to refine strategies and improve response times.

5.10. Crisis Management Framework

•  Description: Establish a comprehensive crisis management plan that includes protocols for communication, decision-making, and recovery.
•  Implementation: Develop a crisis response team with clear roles and responsibilities. Create detailed action plans for different types of crises, including communication strategies for stakeholders.⁴²

Here’s the information organized in a table format: face of sanctions.

 

 

 

Table:2 information organized⁴²

 
 

To successfully implement these strategies, a proactive mindset and dedication to ongoing improvement are essential. Conducting regular evaluations and updates will help ensure that the pharmaceutical supply chain stays resilient against challenges such as sanctions and other disruptions.

 

 

 

Table 3: Research and Development (R&D)⁴²

Aspects	Detail
Definition of Pharmaceutical Resilience 17	Capacity to withstand and recover from disruptions while continuing to innovate and deliver essential medications
Key Components of R&D Resilience
A. Flexible R&D Strategies	- Adaptive planning for changing conditions  - Cross-functional teams for enhanced collaboration
B. Robust Supply Chain Management28	- Diversified supply sources to mitigate risks  - Local sourcing to reduce global disruption vulnerability
C. Investment in Technology	Digital tools (AI, machine learning) for drug discovery  - Cloud computing for improved collaboration and data sharing

 

Table:4. Innovations Driving Resilience⁴²

 

A. mRNA Technology	Rapid development of mRNA vaccines (e.g., COVID-19) showcasing quick adaptation to health threats.
B. Platform Technologies	Versatile platforms allowing rapid modification for new therapies in response to emerging diseases.
C. Real-World Evidence (RWE)	Leveraging real-world data to inform development and enhance clinical trial designs.
Regulatory Adaptations	- Expedited approval processes for public health emergencies  - Adaptive trial designs for increased efficiency
Case Studies of Resilience	- COVID-19 response: rapid vaccine development by Pfizer and Moderna  - Antibiotic R&D revitalization in response to resistance concerns.

 

Table 5: Challenges to R&D Resilience⁴²

 

A. Funding Limitations	Economic pressures leading to reduced R&D budgets.
B. Regulatory Hurdles	Complex regulatory environments slowing down drug development.
C. Intellectual Property Concerns	Balancing innovation needs with proprietary technology protection.

 

Table: 6. Building a Resilient R&D Culture⁴²

A. Talent Development	Investing in workforce training and skill development.
B. Fostering Innovation	Encouraging creativity and risk-taking in R&D initiatives.
C. Stakeholder Engagement	Maintaining relationships with regulators, healthcare providers, and patients for better understanding of needs.

 

Table 7: Measuring Resilience in R&D⁴²

A. Time to Market	Speed of bringing new therapies to market.
B. Clinical Trial Success Rates	Monitoring success rates in clinical phases.
C. Supply Chain Disruptions	Analyzing frequency and impact of supply chain issues on production timelines.
Conclusion	R&D is critical for resilience; ongoing adaptation and investment will sustain innovation and public health advancements.

 

6. Innovations in pharmaceutical resilience

The pharmaceutical industry is experiencing transformative innovations aimed at enhancing resilience, particularly in response to recent global challenges such as the COVID-19 pandemic. One major area of change is digital transformation. The rise of telehealth and remote monitoring has revolutionized patient care, providing greater access and continuity, which allows pharmaceutical companies to respond swiftly to patient needs. Additionally, advanced data analytics and artificial intelligence (AI) are increasingly utilized in drug discovery, clinical trials, and personalized medicine. AI technologies streamline processes, predict outcomes, and identify potential drug interactions, significantly improving efficiency and safety throughout the drug development lifecycle.¹⁸

Supply chain innovations are also critical to fostering resilience. The adoption of blockchain technology improves transparency and traceability, reducing the risk of counterfeit drugs and ensuring safe product delivery. Moreover, pharmaceutical companies are diversifying their supplier bases to mitigate risks associated with over-reliance on single sources, thereby strengthening supply chain robustness. Agile manufacturing techniques, including modular and flexible manufacturing, allow companies to rapidly adapt production lines to meet shifting market demands. Continuous manufacturing, which enables real-time production rather than traditional batch processing, further enhances efficiency and reduces lead times.

In terms of regulatory flexibility, the pharmaceutical sector is benefiting from adaptive trial designs, which allow modifications based on interim results, facilitating quicker drug approvals while maintaining safety standards. Regulatory agencies are also promoting accelerated approval pathways, such as the FDA’s Breakthrough Therapy designation, to expedite the development of drugs addressing unmet medical needs. Collaboration and partnerships are becoming increasingly vital, with public-private partnerships enhancing research and development efforts, particularly in response to global health crises. Forming consortia for drug development allows companies to share resources and knowledge, reducing costs and accelerating the development of new therapies.

A focus on patient-centric approaches is reshaping how pharmaceutical companies engage with their customers. Real-world evidence (RWE) gathered from everyday settings is instrumental in understanding treatment efficacy, thereby supporting better decision-making and regulatory approvals. Additionally, patient engagement platforms leveraging digital tools enhance adherence and provide invaluable feedback throughout the drug development process. Sustainability initiatives are also gaining traction, with an emphasis on green chemistry to minimize waste and energy consumption, as well as exploring circular economy models that recycle materials and reduce environmental impact.³⁶

Advanced therapies, including gene and cell therapies, are transforming treatment paradigms by offering personalized medicine solutions for previously untreatable conditions. The success of mRNA technology, particularly in vaccines, has opened doors for its application in treating various diseases, including cancer. To further bolster resilience, pharmaceutical companies are investing in workforce development and crisis management planning. By fostering a culture of resilience and preparing for potential disruptions, organizations can adapt more effectively to rapid changes and unforeseen challenges.

Overall, these innovations collectively position the pharmaceutical industry to navigate current obstacles and prepare for future uncertainties, ensuring the continuous delivery of safe and effective therapies to patients around the globe.

6.1. Process of Innovation:-

The process of innovation in pharmaceutical resilience involves a structured approach designed to enhance adaptability and responsiveness in the face of challenges. Here’s a streamlined overview of the key stages:

1. Challenge Identification
2. Market Analysis: Assess vulnerabilities in the current landscape, including supply chain issues and regulatory hurdles.
3. Stakeholder Feedback: Gather insights from patients, healthcare professionals, and industry experts to pinpoint unmet needs and opportunities for improvement.⁴²
4. Research and Development (R&D)
5. Technology Exploration: Investigate emerging technologies such as AI, machine learning, and blockchain that could enhance processes or product development.
6. Collaborative Initiatives: Form partnerships with academic institutions and tech companies to pool resources and expertise for innovative solutions.
7. Concept Development

Prototyping: Create initial prototypes for new technologies or processes, allowing for early testing and refinement - Pilot Studies: Implement small-scale pilot programs to evaluate feasibility and effectiveness in real-world conditions.

4. Regulatory Engagement
5. Proactive Communication: Engage with regulatory agencies early to understand requirements and streamline approval processes.
6. Adaptive Trials: Utilize flexible trial designs to accommodate changes based on preliminary results, expediting approval timelines.
7.  Implementation
8. Cross-Functional Collaboration: Establish teams from various departments (R&D, manufacturing, marketing) to ensure smooth integration of innovations.
9. Training Programs: Provide training to staff on new technologies and processes to ensure effective adoption.
10. Monitoring and Feedback
11. Performance Metrics: Set clear KPIs to evaluate the impact of innovations on efficiency, patient outcomes, and cost-effectiveness.
12. Continuous Improvement: Establish feedback loops for ongoing assessment and refinement based on stakeholder input.
13. Scaling Innovation
14. Strategic Scaling: Develop plans to expand successful innovations across the organization and into new markets.
15. Resource Allocation: Allocate necessary resources to support the growth and sustainability of successful initiatives.
16. Sustainability Focus
17. Integrating Sustainability: Embed sustainable practices throughout the innovation process, from materials sourcing to manufacturing.
18. Crisis Preparedness: Create robust crisis management strategies to quickly address future disruptions and ensure business continuity.

This innovation process emphasizes adaptability, collaboration, and a commitment to patient-centered solutions, allowing pharmaceutical companies to enhance their resilience and effectively respond to evolving challenges in the healthcare landscape

7. Challenges to R&D Resilience

Research and Development (R&D) resilience in the pharmaceutical industry faces a multitude of challenges that can significantly hinder innovation and responsiveness to market needs. One major challenge is regulatory complexity. The pharmaceutical sector is subject to stringent regulations that vary across regions, making navigation a complex task that can delay R&D timelines and escalate costs. Furthermore, evolving guidelines from regulatory agencies regarding data requirements and safety protocols can create additional uncertainty, necessitating adjustments to ongoing projects.⁴⁹

Funding constraints also pose a significant hurdle. The high costs associated with drug development can run into billions of dollars and take many years, which can restrict the scope of research initiatives, particularly in an environment where investors may be wary of funding projects lacking immediate potential for returns. This concern is compounded by the technical challenges inherent in drug development; the process involves multiple stages—discovery, preclinical testing, clinical trials, and regulatory approval—each fraught with its own risks. Additionally, biological variability among patients can complicate the development of effective therapies, often leading to failures in clinical trials.

Market dynamics further complicate the R&D landscape. The rapid pace of technological advancements can outstrip the capacity of R&D teams to adapt and integrate new tools effectively, while competitive pressures to bring new drugs to market quickly can result in rushed processes that increase the likelihood of errors and regulatory challenges. Supply chain vulnerabilities are another critical issue, as dependency on external suppliers for raw materials and active pharmaceutical ingredients (APIs) creates potential bottlenecks. Global disruptions—such as pandemics, geopolitical tensions, or natural disasters—can severely impact the availability of essential materials needed for R&D.¹⁶

Moreover, talent acquisition and retention present ongoing challenges. There is a growing demand for skilled professionals in areas such as bioinformatics and data science, leading to significant talent shortages that can impede R&D efforts. High turnover rates in this competitive job market can result in the loss of expertise and continuity in projects, further complicating the development process. Data management issues, including data silos across different departments, hinder collaboration and limit the ability to leverage data effectively for decision-making. Increasing regulatory scrutiny regarding data privacy also complicates the use of patient data in R&D, particularly during clinical trials.

Patient recruitment and retention is another critical challenge. Finding eligible participants for clinical trials can be difficult, especially in the context of rare diseases or specific demographics. Ensuring patient adherence and retention throughout the duration of trials is crucial, yet can be challenging, leading to delays or incomplete data. Ethical considerations are paramount as well, with the need to maintain high ethical standards in research—particularly concerning human subjects—introducing additional complexity and potential delays. Public perception also plays a role; growing scrutiny regarding pharmaceutical practices and concerns about drug pricing can negatively impact the reputation of R&D initiatives.

Finally, global health crises, such as the COVID-19 pandemic, pose unique challenges to R&D resilience. Such emergencies can disrupt ongoing research efforts and shift focus toward immediate public health needs, diverting resources away from long-term projects. During these crises, the allocation of R&D resources may need to be adjusted, impacting overall research agendas. To strengthen R&D resilience, pharmaceutical companies must adopt a multifaceted approach that includes fostering collaboration across sectors, investing in new technologies, enhancing regulatory engagement, and prioritizing talent development. By addressing these challenges effectively, the industry can enhance its capacity for innovation and better meet the evolving needs of patients and the healthcare system.²³

pharmaceutical resilience is the industry’s ability to adapt to challenge like supply chain disruption and public health emergencies. Key factors include flexibility in production, investment in technology for efficiency, collaboration among stakeholders, adaptability to regulatory changes, and focus on sustainability. Enhancing the pharmaceutical resilience is essential for ensuring the continuous availability for safe and effective medication, improving public health outcomes.¹⁷

Acknowledgement: It’s our privilege to express the profound sense of gratitude and cordial thanks to our respected Staff Ms. Pranjali Ugale and all supportive staff for providing   the    necessary facilities   to   complete this review.

Funding: Nil.

Conflict of Interest: The   authors    declare   no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Author Contributions: All    authors   have   equal contribution in the preparation of manuscript and compilation.

Source of Support: Nil 

Ethics approval and consent to participate: Not applicable 

Informed Consent Statement: Not applicable. 

Data Availability Statement: The data supporting in this paper are available in the cited references.

References:

1. Kamalahmadi M, Shekarian M, Mellat PM. The impact of flexibility and redundancy on improving supply chain resilience to disruptions. Int J Prod Res. 2021:1-29. https://doi.org/10.1080/00207543.2021.1883759

2. Shekarian M, Mellat PM. An Integrative approach to supply chain disruption risk and resilience management: a literature review. Int J Log Res Appl. 2021;24(5):427-55. https://doi.org/10.1080/13675567.2020.1763935

3. Hosseini S, Ivanov D, Dolgui A. Ripple effect modelling of supplier disruption: integrated Markov chain and dynamic Bayesian network approach. Int J Prod Res. 2020;58(11):3284-303. https://doi.org/10.1080/00207543.2019.1661538

4. Fridell M, Edwin S, Von Schreeb J, Saulnier DD. Health system resilience: what are we talking about? A scoping review mapping characteristics and keywords. Int J Health Policy Manag. 2020;9(1):6-16. https://doi.org/10.15171/ijhpm.2019.71 PMid:31902190 PMCid:PMC6943300

5. Alqudah S, Shrouf H, Suifan T, Alhyari S. A moderated mediation model of lean, agile, resilient, and green paradigms in the supply chain. Int J Sup Chain Mgt. 2020;9(4):1-16.

6. Yaroson EV, Breen L, Hou J, Sowter J. Resilience strategies and the pharmaceutical supply chain: the role of agility in mitigating drug shortages. In: Pharmaceutical supply chains-medicines shortages. Cham: Springer; 2019. p. 249-56. https://doi.org/10.1007/978-3-030-15398-4_18

7. Aloosh M, Salavati A, Aloosh A. Economic sanctions threaten population health: the case of Iran. Public Health. 2019;169:10-3. https://doi.org/10.1016/j.puhe.2019.01.006 PMid:30771721

8. Kwon I-W, Kim S-H. Humanitarian supply chain/logistics: roadmap to effective relief effort. J Int Interdiscip Bus Res. 2018;5(1):95-109. https://doi.org/10.58809/YQXZ7481

9. Zhu Q, Krikke H, Caniëls MC. Integrated supply chain risk management: a systematic review. Int J Logist Manag. 2017;28(4):1123-41. https://doi.org/10.1108/IJLM-09-2016-0206

10. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):1-13. https://doi.org/10.1177/1609406917733847

11. McCrae N, Purssell E. Is it really theoretical? A review of sampling in grounded theory studies in nursing journals. J Adv Nurs. 2016;72(10):2284-93. https://doi.org/10.1111/jan.12986 PMid:27113800

12. Haavisto I, Kovács G, Spens K. Supply chain management for humanitarians: tools for practice: Kogan Page Publishers; 2016.

13. Bahrin NLZ, Hassan Y, Abd Majeed AB, Zulkifli NW, Ahmad A. Pharmaceutical Fiscal Sustainability: Review of Malaysia's Essential Medicines List. 2nd International Conference on Public Policy; Università Cattolica del Sacro Cuore, Milan, Italy 2015.

14. Ochi S, Hodgson S, Landeg O, Mayner L, Murray V. Medication supply for people evacuated during disasters. J Evid Based Med. 2015;8(1):39-41. https://doi.org/10.1111/jebm.12138 PMid:25594870

15. Privett N, Gonsalvez D. The top ten global health supply chain issues: perspectives from the field. Oper Res Health Care. 2014;3(4):226-30. https://doi.org/10.1016/j.orhc.2014.09.002

16. He X, Hu W. Modeling relief demands in an emergency supply chain system under large-scale disasters based on a queuing network. Sci World J. 2014;2014:1-12. https://doi.org/10.1155/2014/195053 PMid:24688367 PMCid:PMC3933051

17. Harrington L, Smith R. The resilient supply chain. DHL Supply Chain. 2014.

18. Aigbogun O, Ghazali Z, Razali R. A framework to enhance supply chain resilience the case of Malaysian pharmaceutical industry. Glob Bus Manag Res. 2014;6(3):219-28.

19. ECD. Guidelines for resilience systems analysis. OECD Publishing Paris; 2014.

20. Bazregar R, Khankeh H, Ahmadi S, Hosseini M, Rahgozar M, Moradian M. The evaluation of application of coordination based disaster response model in Rajaye hospital disaster preparedness. Iran J Nurs Res. 2013;8(29):10-8.

21. Ghatari AR, Mehralian G, Zarenezhad F, Rasekh HR. Developing a model for agile supply: an empirical study from Iranian pharmaceutical supply chain. Iran J Pharm Res: IJPR. 2013;12(Suppl):193.

22. Gupta A, Evans GW, Heragu SS. Simulation and optimization modeling for drive-through mass vaccination-a generalized approach. Simul Model Pract Theory. 2013;37:99-106. https://doi.org/10.1016/j.simpat.2013.06.004

23. Dash SR, Mishra US, Mishra P. Emerging issues and opportunities in disaster response supply chain management. Int J Supply Chain Manag. 2013;2(1):55-61.

24. Chen J, Sohal AS, Prajogo DI. Supply chain operational risk mitigation: a collaborative approach. Int J Prod Res. 2013;51(7):2186-99. https://doi.org/10.1080/00207543.2012.727490

25. Ghatari AR, Mehralian G, Zarenezhad F, Rasekh HR. Developing a model for agile supply: an empirical study from Iranian pharmaceutical supply chain. Iran J Pharm Res. 2013;12(Suppl):193-205.

26. Abdollahiasl A, Jaberidoost M, Farshchi A. PHP13 affordability of antibacterial medicines in Iran during 2001-2010. Value Health. 2012;15(7):A611. https://doi.org/10.1016/j.jval.2012.08.064

27. Ji G, Zhu C. A study on emergency supply chain and risk based on urgent relief service in disasters. Syst Eng Proc. 2012;5:313-25. https://doi.org/10.1016/j.sepro.2012.04.049

28. Gary L. Supply chain resiliency: how prepared is your organization? : Marsh Inc.; 2012.

29. Rachaniotis NP, Dasaklis TK, Pappis CP. A deterministic resource scheduling model in epidemic control: a case study. Eur J Oper Res. 2012;216(1):225-31. https://doi.org/10.1016/j.ejor.2011.07.009

30. Manuj I, Pohlen TL. A reviewer's guide to the grounded theory methodology in logistics and supply chain management research. Int J Phys Distrib Logist Manag. 2012;42(8/9):784-803. https://doi.org/10.1108/09600031211269758

31. Torabizadeh M, Khatami Rad M, Noshadi A. Effect of information system strategies on supply chain strategies and supply chain performance. World Acad Sci, Eng Technol. 2012;61:940-5.

32. Roberts MJ, Reich MR. Last mile logistics for essential drugs: the case of Zambia. In: Roberts M, Reich M, editors. Pharmaceutical reform: a guide to improving performance and equity. Washington, DC: World Bank; 2011. https://doi.org/10.1596/9780821387603_D PMid:21396507 PMCid:PMC5783556

33. Ghanbari V, Maddah S, Khankeh H, Karimloo M. The effect of a disaster nursing education program on nurses' preparedness for responding to probable natural disasters. Iran J Nurs. 2011;24(73):72-80.

34. Bendavid Y, Boeck H. Using RFID to improve hospital supply chain management for high value and consignment items. Proc Comput Sci. 2011;5:849-56. https://doi.org/10.1016/j.procs.2011.07.117

35. Chabner BA. Drug shortages-a critical challenge for the generic-drug market. N Engl J Med. 2011;365(23):2147-9. https://doi.org/10.1056/NEJMp1112633 PMid:22040167

36. Mahendran H, Narasimhan K, Nagarajan N, Gopinath S, editors. Investigation of supply chain risk in the Indian pharmaceutical industry: a case study. Proceedings of the World Congress on Engineering; 2011.

37. Roberts MJ, Reich MR. Last mile logistics for essential drugs: the case of Zambia. In: Roberts M, Reich M, editors. Pharmaceutical reform: a guide to improving performance and equity. Washington, DC: World Bank; 2011. https://doi.org/10.1596/9780821387603_D PMid:21396507 PMCid:PMC5783556

38. Çakıcı ÖE, Groenevelt H, Seidmann A. Using RFID for the management of pharmaceutical inventory-system optimization and shrinkage control. Decision Support Syst. 2011;51(4):842-52. https://doi.org/10.1016/j.dss.2011.02.003

39. Yu X, Li C, Shi Y, Yu M. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy. 2010;97(1):8-15. https://doi.org/10.1016/j.healthpol.2010.02.010 PMid:20307912

40. Brandeau ML, McCoy JH, Hupert N, Holty J-E, Bravata DM. Recommendations for modeling disaster responses in public health and medicine: a position paper of the Society for Medical Decision Making. Med Decis Making. 2009;29(4):438-60. https://doi.org/10.1177/0272989X09340346 PMid:19605887 PMCid:PMC3699691

41. Dong S, Xu SX, Zhu KX. Research note-information technology in supply chains: the value of it-enabled resources under competition. Inf Syst Res. 2009;20(1):18-32. https://doi.org/10.1287/isre.1080.0195

42. Graves S, Lei L, Melamed B, Pinedo M, Qi L, Shen Z, et al., editors. New challenges to emergency management of pharmaceutical/healthcare supply chain disruptions. DHS Workshop on Incident Management, Resource Management, and Supply Chain Management; 2009.

43. Lin Y-H, Batta R, Rogerson A, Blatt A, Flanigan M. Logistic model for delivery of critical items in a disaster relief operation: heuristic approaches2009. 1-42 p.

44. Mosavi G. The preparedness of rehabilitation centers in disasters in Zanjan province. Social Welfare Masters Thesis: University of Social Welfare and Rehabilitation Science; 2008.

45. Jahre M, Heigh I, editors. Does the current constraints in funding promote failure in humanitarian supply chains? Supply Chain Forum: an International Journal; 2008: Taylor & Francis. https://doi.org/10.1080/16258312.2008.11517198

46. Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21(2):123-31. https://doi.org/10.1093/heapol/czj011 PMid:16415339

47. Tang CS. Robust strategies for mitigating supply chain disruptions. Int J Log Res Appl. 2006;9(1):33-45. https://doi.org/10.1080/13675560500405584

48. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ. 2006;84:371-5. https://doi.org/10.2471/BLT.06.031153 PMid:16710546 PMCid:PMC2627335

49. Christopher M, Peck H. Building the resilient supply chain. Int J Logist Manag. 2004;15(2):1-14. https://doi.org/10.1108/09574090410700275

50. Mclaren TS, Head MM, Yuan Y. Supply chain management information systems capabilities. An exploratory study of electronics manufacturers. Inf Syst E-business Manag. 2004;2(2-3):207-22. https://doi.org/10.1007/s10257-004-0035-5

51. World Health Organization. Equitable access to essential medicines: a framework for collective action. Geneva: World Health Organization; 2004.

52. World Health Organization. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization; 2001

53. Pan American Health Organization. Natural disasters: protecting the public's health. PAHO Washington; 2000.

54. Pan American Health Organization. Natural disasters: protecting the public's health. PAHO Washington; 2000.

55.Christopher M, Jüttner U. Developing strategic partnerships in the supply chain: a practitioner perspective. Eur J Purchasing Supply Manag. 2000;6(2):117-27. https://doi.org/10.1016/S0969-7012(99)00038-6

56. Corbin JM. The Corbin and Strauss chronic illness trajectory model: an update. Sch Inq Nurs Pract. 1998;12(1):33-41.

57. Van der Stuyft P, De Vos P, Hiderbrand K. USA and shortage of food and medicine in Cuba. Lancet. 1997;349(9048):363. https://doi.org/10.1016/S0140-6736(05)62872-3 PMid:9024412

58. Guba EG, Lincoln YS. Competing paradigms in qualitative research. In: Lincoln DYS, editor. Handbook of qualitative research. Thousand Oaks: Sage Publications Inc.; 1994. p. 105-17.

59. Strauss A, Corbin JM. Basics of qualitative research: grounded theory procedures and techniques: Sage Publications Inc.; 1990.

60. Barnett J. Supply of medicines text book of hospital pharmacy. London: Blackwell; 1980. p. 277-330.